Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 3, 2011, Pages 307-318

  Li, Pei ^a   Yang, Yabing ^a   Liu, Meilin ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

atherosclerosis; NADPH oxidase; red yeast rice; tissue factor; xuezhikang

Indexed keywords

DIPHENYLIODONIUM SALT; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; OXIDIZED LOW DENSITY LIPOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THROMBOPLASTIN; XUEZHIKANG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CHOLESTEROL DIET; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; HEART PROTECTION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; AORTA; BIOLOGICAL AGENTS; BLOOD COAGULATION TESTS; CELL SURVIVAL; CHOLECALCIFEROL; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; LOVASTATIN; MACROPHAGES; MALE; MICE; NADPH OXIDASE; ORYZA SATIVA; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; THROMBOPHILIA; THROMBOPLASTIN; VITAMINS;

EID: 80052703315     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182244a2d     Document Type: Article

References (22)

1. Redondo M, Carroll VA, Mauron T, et al. Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events. Blood Coagul Fibrinolysis. 2001;12:17-24. (Pubitemid 32150247)
2. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification ofactive tissue factor in human coronary atheroma Circulation. 1996;94:1226-1232. (Pubitemid 26307246)
3. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: awidespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-1207. (Pubitemid 38891569)
4. Vendrov AE, Madamanchi NR, Hakim ZS, et al. Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. Circ Res. 2006;98:1254-1263. (Pubitemid 43948080)
5. Rivera J, Sobey CG, Walduck AK, et al. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep. 2010;15:50-63.
6. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113: 722-731.
7. Breitenstein A, Tanner FC, Lüscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J. 2010;74:3-12.
8. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153-183. (Pubitemid 32458157)
9. Zhang XQ, Zhou FR, Ji Ming S. HPLC analysis of lovastatin concentration in xuezhikang capsule and other red yeast rice. China J Chin Materia Medica (Chin). 1999;22:222-224.
10. Lu Z, Kou W, Du B, et al. Effect ofxuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689-1693.
11. Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004; 110:915-920. (Pubitemid 39128616)
12. Li JJ, Hu SS, Fang CH, et al. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta. 2005;352:217-224
13. National Expert Consensus Institute. Expert consensus ofxuezhikang on clinical applications. Chin JIntern Med. 2009;48:171-174.
14. Hong X, Li D, Wu L. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2007;34:27-35. (Pubitemid 46069582)
15. Luo Y, Chen G, Li B, et al. Dietary intervention with AHP, a functional formula diet, improves both serum and hepatic lipids profile in dyslipidemia mice. JFood Sci. 2009;74:189-195.
16. Cross AR, Jones OT. The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labeling of a component polypeptide of the oxidase. Biochem J. 1986;237:111-116. (Pubitemid 16063096)
17. Chi L, Gibson G, Peng YW, et al. Characterization ofatissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits. JThromb Haemost. 2004;2:85-92. (Pubitemid 40185624)
18. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311:501-505. (Pubitemid 14059351)
19. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscl Thromb Vasc Biol. 2004;24:23-28. (Pubitemid 38082407)
20. Keaney JF Jr. Oxidative stress and the vascular wall: NADPH oxidases take center stage. Circulation. 2005;112:2585-2588. (Pubitemid 41532593)
21. Monetti M, Canavesi M, Camera M, et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apo E-deficient mice. Pharmacol Res. 2007;55:441-449. (Pubitemid 46560397)
22. Schulze PC, Lee RT. Oxidative stress and atherosclerosis. Curr Atheroscler Rep. 2005;7:242-248. (Pubitemid 40796758)